Exchange & Returns Information


(0)
| Generic For | XIGDUO |
|---|---|
| Active Ingredient | DAPAGLIFLOZIN|METFORMIN |
| Strength | 10MG|500MG |
| Manufacturer | HEALING PHARMA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| ★ Best Value 1 BOX - 100 TABLETS | $ 0.33 | $ 32.90 |
$ 27.97
Apply ZARVY26 (-15%)
You save $ 4.94
|
||
| ★ Best Value 2 BOXES - 200 TABLETS | $ 0.29 |
12% $ 65.80
$ 58.00
|
$ 49.30
Apply ZARVY26 (-15%)
You save $ 8.70
|
||
| ★ Best Value 3 BOXES - 300 TABLETS | $ 0.26 |
20% $ 98.70
$ 78.90
|
$ 67.07
Apply ZARVY26 (-15%)
You save $ 11.84
|


Reference information will be available soon.
Dapasmart M 10/500mg is a combination medication for Type 2 diabetes management, developed by Healing Pharma. It contains Dapagliflozin 10mg (an SGLT-2 inhibitor) and Metformin 500mg (a first-line diabetes treatment). This dual-action therapy lowers blood sugar levels by inhibiting glucose production in the liver and increasing glucose excretion through urine. Additionally, it supports weight management, cardiovascular protection, and potential liver health benefits.
- First-Line Diabetes Treatment: Metformin enhances insulin sensitivity and reduces glucose production in the liver. - Blood Sugar Regulation: Dapagliflozin helps remove excess glucose through urine by blocking its reabsorption in the kidneys. - Weight Management Support: Aids glycemic control while promoting potential weight reduction. - Cardiovascular Benefits: Dapagliflozin may help lower the risk of heart failure and cardiovascular complications. - Liver Health Support: Potentially beneficial in managing non-alcoholic fatty liver disease (NAFLD).
Dapasmart M 10/500mg works through a dual mechanism: - Metformin (First-Line Therapy) reduces glucose production in the liver and enhances insulin sensitivity. - Dapagliflozin (SGLT-2 Inhibitor) blocks glucose reabsorption in the kidneys, leading to increased glucose excretion and improved blood sugar control. These combined mechanisms help improve glycemic control, metabolic balance, and cardiovascular protection.
- Take one tablet (10mg/500mg) once or twice daily, with meals, to reduce stomach discomfort. - Designed for Type 2 diabetes management, offering dual-action blood sugar control. - Helps maintain glycemic balance, while supporting potential weight reduction. - Ensure proper hydration, as increased urination is a common effect due to SGLT-2 inhibition.
- Store in a cool, dry place, away from direct sunlight, heat, and moisture. - Keep the tablets in their original packaging to maintain effectiveness. - Ensure the medication is out of reach of children and pets.
While generally well-tolerated, some users may experience mild side effects such as: - Increased urination and thirst (due to Dapagliflozin) - Mild dehydration or dizziness - Gastrointestinal discomfort, nausea, or diarrhea (due to Metformin) - Urinary tract infections (UTIs) and genital yeast infections - Low blood sugar when taken with other diabetes medications Important: Pregnant women should consult their doctor before handling or using this medication. If severe side effects occur, such as lactic acidosis or ketoacidosis, seek medical attention immediately.
Reviewed by 0 Users
Write a Review:
✓ The 'Write a Review' button appears only when an order includes this product and the product item in that order is marked as 'Delivered'.
✓ Clicking the button will redirect you to 'My Account > Orders > Orders Processing', where you can leave a review for a delivered item.
💡 Each product item can be reviewed only once, after it has been marked as 'Delivered'.
Multiple orders:
✓ If you bought this product more than once on different days, you can write a separate review for each order.
💡 When Order A is marked 'Delivered', the button takes you to Order A's details page.
Later, when Order B is also marked Delivered, the button stays active and takes you to Order B's details page for another review.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
Loading...
Loading...
Loading...